CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19
NCT04356482 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2020-06-05
Summary
The present study will try to respond first in an initial phase, what is the minimum effective dose necessary of convalescent plasma for getting better in severly ill (not intubated) or very severely ill (intubated) patients.
Once the dose will be determined by each type of patient group (severely ill vs. very severely ill) has been determined, phase 2 of the study will begin, where the safety and efficacy of the use of plasma will be evaluated based on clinical, imaging and laboratory criteria.
So, our hypotheses are:
1. Is there a minimum effective dose to treat seriously ill patients with convalescent plasma with COVID-19?
2. the plasma dose with the minimum effective effect will improve the clinical, laboratory and clearance conditions of the presence of the virus in the severely ill patient?
Conditions
- COVID-19
- SARS-CoV 2
- Convalescence
- Plasma
- Doses
Interventions
- BIOLOGICAL
-
convalescent plasma
In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case. In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated.
Sponsors & Collaborators
-
SECRETARIA DE SALUD DEL ESTADO DE SONORA
collaborator UNKNOWN -
CENTRO ESTATAL DE LA TRANSFUSION SANGUINEA
collaborator UNKNOWN -
HOSPITAL CENTRAL NACIONAL PEMEX NORTE
collaborator UNKNOWN -
HOSPITAL DE ZONA No. 2 IMSS
collaborator UNKNOWN -
HOSPITAL DE ZONA No.14 IMSS
collaborator UNKNOWN -
HOSPITAL GENERAL DEL ESTADO DE SONORA
collaborator UNKNOWN -
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
lead OTHER_GOV
Principal Investigators
-
Luis M Villela, MD · ISSSTESON
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-20
- Primary Completion
- 2020-11-30
- Completion
- 2020-12-31
Countries
- Mexico
Study Locations
More Related Trials
-
COVID-19 Convalescent Plasma Therapy
NCT04747158 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Convalescent Plasma for Patients With COVID-19
NCT04385199 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma for Patients With COVID-19: A Pilot Study
NCT04332380 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection
NCT04375098 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia
NCT04358783 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)
NCT04391101 ·Status: UNKNOWN ·Phase: PHASE3
-
Use of Convalescent Plasma for COVID-19
NCT04408040 ·Status: TERMINATED ·Phase: PHASE2
-
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
NCT04474340 ·Status: UNKNOWN ·Phase: PHASE1
-
Convalescent Plasma for COVID-19 Patients
NCT04516954 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Convalescent Plasma for the Treatment of COVID-19
NCT04389710 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
NCT04392232 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma in the Treatment of Covid-19
NCT04730401 ·Status: UNKNOWN ·Phase: PHASE2
-
Convalescent Plasma in the Treatment of COVID 19
NCT04343261 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma Trial in COVID -19 Patients
NCT04356534 ·Status: COMPLETED ·Phase: NA
-
Treatment of Patients With COVID-19 With Convalescent Plasma
NCT04415086 ·Status: COMPLETED ·Phase: PHASE2
-
Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19
NCT04385186 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients
NCT04354831 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma for Severe COVID-19 Patients
NCT04547660 ·Status: COMPLETED ·Phase: PHASE3
-
Convalescent Plasma to Limit Coronavirus Associated Complications
NCT04325672 ·Status: WITHDRAWN ·Phase: PHASE2
-
Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)
NCT04342182 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
NCT04547127 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19
NCT04433910 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma for COVID-19
NCT04365439 ·Status: UNKNOWN ·Phase: NA
-
Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)
NCT04360486 ·Status: NO_LONGER_AVAILABLE
-
COVID-19 Convalescent Plasma
NCT04340050 ·Status: COMPLETED ·Phase: EARLY_PHASE1